Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (ticker: ENSC) is a pharmaceutical company operating in the life sciences and specialty drug development sector, with a focus on abuse-deterrent formulations for controlled substances including opioids. The company filed a Form 10-Q with the SEC on November 7, 2019, accession number 0001213900-19-022353, reflecting its standing as a reporting public company at that time. Ensysce reached public markets through a special purpose acquisition company transaction, a path common among clinical-stage pharmaceutical companies seeking capital without a traditional IPO. The company's proprietary platform technologies target opioid misuse prevention, placing it within the growing abuse-deterrent therapeutics niche. Sign up on SpacDesk for full filing history, sponsor details, and deal-level data on Ensysce Biosciences and the broader SPAC universe.